Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 159

Results For "report"

1824 News Found

Roche retains its sustainability ranking in the Dow Jones Sustainability Indices
Sustainability | November 15, 2021

Roche retains its sustainability ranking in the Dow Jones Sustainability Indices

The company performed particularly well in operational eco-efficiency, environmental and social reporting


BGS Gleneagles Global hospital opens women’s cancer care centre
Hospitals | November 15, 2021

BGS Gleneagles Global hospital opens women’s cancer care centre

Early detection of breast cancer increases survival rate by 95 per cent


USAID announces Momentum country programme
Public Health | November 15, 2021

USAID announces Momentum country programme

The initiative will engage adolescents and youth of India in decisions about their reproductive health


Alarming rise in diabetes amongst children and adolescents in India
News | November 14, 2021

Alarming rise in diabetes amongst children and adolescents in India

The rise in cases amongst the young is a cause for concern. A few specialists gave us a perspective on the issue


Aster DM Healthcare PAT at Rs 107 cr. in Q2FY22
News | November 13, 2021

Aster DM Healthcare PAT at Rs 107 cr. in Q2FY22

Aster DM Healthcare announced its financial results for the quarter ended September 30, 2021


Natco Pharma PAT at Rs 65.1 cr. in Q2FY22
News | November 12, 2021

Natco Pharma PAT at Rs 65.1 cr. in Q2FY22

Natco Pharma has reported consolidated financial results for the period ended September 30, 2021


Solara Active Pharma Sciences PAT slides to Rs 29.71 cr in Q2FY22
News | November 12, 2021

Solara Active Pharma Sciences PAT slides to Rs 29.71 cr in Q2FY22

Solara Active Pharma Sciences has reported consolidated financial results for the period ended September 30, 2021.


Covaxin well tolerated with no safety concerns: Lancet
News | November 12, 2021

Covaxin well tolerated with no safety concerns: Lancet

Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%


Metropolis Healthcare PAT at Rs 58.26 cr in Q2FY22
News | November 11, 2021

Metropolis Healthcare PAT at Rs 58.26 cr in Q2FY22

Metropolis Healthcare has reported consolidated financial results for the period ended September 30, 2021


Clinical study shows ViroStop spray prevents Covid-19
News | November 11, 2021

Clinical study shows ViroStop spray prevents Covid-19

Evidence also shows better immune response to virus among users of spray